Erivedge 150 mg, 28 capsules (Vismodegib 150 mg per capsule) by Roche.
Indications: Symptomatic metastatic or locally advanced basal cell carcinoma not suitable for surgery or radiotherapy.
Administration: Oral: 150 mg once daily. Strict pregnancy-prevention programme applies.
Storage: Store below 25–30 °C in the original package. Keep out of the sight and reach of children.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Roche |
| Active ingredient | Vismodegib 150 mg per capsule — Hedgehog pathway inhibitor. |
| Strength & pack | 28 hard capsules. |
| Form | Hard capsules |
| Storage | Store below 25–30 °C in the original package. Keep out of the sight and reach of children. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |